Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
Cecchi F, Rex K, Schmidt J, Vocke CD, Lee YH, Burkett S, Baker D, Damore MA, Coxon A, Burgess TL, Bottaro DP.
Cecchi F, et al. Among authors: burgess tl.
Cancers (Basel). 2023 Jan 11;15(2):460. doi: 10.3390/cancers15020460.
Cancers (Basel). 2023.
PMID: 36672409
Free PMC article.